Naruto Taira
   Department   Kawasaki Medical School  Kawasaki Medical School, Department of Breast and Thyroid Surgery,
   Position   Professor
Article types 原著
Language English
Peer review Peer reviewed
Title Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
Journal Formal name：Breast cancer (Tokyo, Japan)
Abbreviation：Breast Cancer
ISSN code：18804233/13406868
Domestic / ForeginForegin
Volume, Issue, Page 30(1),pp.56-67
Author and coauthor Yidan Zhu, Takayuki Iwamoto, Yukiko Kajiwara, Yuko Takahashi, Mariko Kochi, Tadahiko Shien, Naruto Taira, Shinichi Toyooka, Hiroyoshi Doihara
Publication date 2023/01
Summary BACKGROUND:Previous studies of immune genomic signatures (IGSs) in breast cancer have attempted to predict the response to chemotherapy or prognosis and were performed using different patient cohorts. The purpose of this study was to evaluate the predictive functions of various IGSs using the same patient cohort that included data for response to chemotherapy as well as the prognosis after surgery.METHODS:We applied five previously described IGS models in a public dataset of 508 breast cancer patients treated with neoadjuvant chemotherapy. The prognostic and predictive values of each model were evaluated, and their correlations were compared.RESULTS:We observed a high proportion of expression concordance among the IGS models (r: 0.56-1). Higher scores of IGSs were detected in aggressive breast cancer subtypes (basal and HER2-enriched) (P < 0.001). Four of the five IGSs could predict chemotherapy responses and two could predict 5-year relapse-free survival in cases with hormone receptor-positive (HR +) tumors. However, the models showed no significant differences in their predictive abilities for hormone receptor-negative (HR-) tumors.CONCLUSIONS:IGSs are, to some extent, useful for predicting prognosis and chemotherapy response; moreover, they show substantial agreement for specific breast cancer subtypes. However, it is necessary to identify more compelling biomarkers for both prognosis and response to chemotherapy in HR- and HER2 + cases.
DOI 10.1007/s12282-022-01397-3
PMID 35994199